This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
tim.hodson Tue, 03/11/2025 - 10:25 March 11, 2025 Caristo Diagnosticshas received U.S. CaRi-Plaque builds on Caristoscore CaRi-Hearttechnology, which a Lancet 2024 study proved can reveal hidden, high-risk markers of CAD progression predicting heart attacks up to a decade before they strike. But with AI, we can change that.
tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has released clinical data that provides new information about how low-dose colchicine, 0.5 mg improved several measures of plaque volume changes over a period of 12 months in patients with stable coronary artery disease, Dr. Budoff continued.
Coronary angiography identified moderate stenosis of the right coronary artery (RCA), without significant flow restriction by invasive pressure wire interrogation. This case emphasises the importance of recognising plaque-associated CAS as a potential trigger for life-threatening arrhythmias, even in the absence of chest pain.
tim.hodson Wed, 02/26/2025 - 10:24 Feb. 25, 2025 Heartflow, Inc. , Coronary computed tomography angiography (CCTA) was a major advancement in CAD diagnostics, helping physicians estimate if a stenosis was significant and requiring intervention. References Centers for Disease Control and Prevention. Heart Disease Facts.
Stroke, Volume 56, Issue Suppl_1 , Page ATP219-ATP219, February 1, 2025. However, few reports have discussed CNs in the context of carotid artery stenosis. However, few reports have discussed CNs in the context of carotid artery stenosis. of patients with moderate to severe carotid artery stenosis who underwent CEA.
Stroke, Volume 56, Issue Suppl_1 , Page ATP342-ATP342, February 1, 2025. Background:Previous research has suggested pericarotid fat density to be significantly linked to atherosclerotic plaque components and cerebrovascular events. Baseline demographics and clinical data of our population were extracted from electronic health records.
Stroke, Volume 56, Issue Suppl_1 , Page A38-A38, February 1, 2025. Background and Purpose:We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type-9 inhibitor for intensive lipid-lowering, on intracranial atherosclerotic stenosis (ICAS).Methods:From 0.11] vs. evolocumab-: 0.02 [0.04-0.07]),
Stroke, Volume 56, Issue Suppl_1 , Page ATP296-ATP296, February 1, 2025. Introduction:Nonstenotic carotid plaque is found in some patients with otherwise cryptogenic stroke (CS) but also in normal individuals and patients with stroke of known cause (KS). Methods of vessel imaging were carotid duplex ultrasound, CTA, and MRA.
tim.hodson Mon, 02/03/2025 - 12:30 January 29, 2025 Roche announced today that the Tina-quant Lipoprotein (a) Gen.2 2 Molarity assay has received 510(k) clearance from the United States Food and Drug Administration (FDA). This will be the first 510(k) cleared test of its kind available in the U.S. 2022 Aug, 80 (9) 934946 Kronenberg F.
Stroke, Volume 56, Issue Suppl_1 , Page AWP205-AWP205, February 1, 2025. The bovine anatomical variation may alter the blood flow dynamics, potentially contributing to the formation and progression of carotid plaques. CTAs were reviewed to assess the carotid stenosis and the anatomy of the aortic arch. N=16, 36.4%; p=0.030).
tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has highlighted clinical data that provides new information about how low-dose colchicine, 0.5 mg improved several measures of plaque volume changes over a period of 12 months in patients with stable coronary artery disease, Dr. Budoff continued.
Stroke, Volume 56, Issue Suppl_1 , Page ATP288-ATP288, February 1, 2025. After age standardization, the prevalence of cIMT, carotid plaque, and carotid stenosis was 23.24%, 16.75%, and 2.36%, respectively, with moderate to severe carotid stenosis observed in 0.49% of all participants.
Stroke, Volume 56, Issue Suppl_1 , Page ATMP54-ATMP54, February 1, 2025. Although carotid plaques can be identified on CT angiography (CTA), interpretation is challenging for frontline physicians. Quantification of plaque volume/composition requires much manual effort. 0.76) for calcific plaque and 0.53 (0.49-0.57)
Stroke, Volume 56, Issue Suppl_1 , Page ATMP10-ATMP10, February 1, 2025. Recently, cilostazol plus other antiplatelet agents combined therapy (CT) has been reported to reduce recurrent stroke, and eicosapentaenoic acid (EPA) has been reported to reduce the risk of cardiovascular events and plaque progression. 41.40) vs. MT: 9.15% (2.69-25.78),
Welcome to 2025 and best wishes for a great academic journey to all readers. Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24) Top 10 Clinical Trials Preventive PCI on Stenosis With Functionally Insignificant Vulnerable Plaque PREVENT (ACC.24)
High Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), aortic stenosis, and all-cause mortality. Elevated Lp(a) is associated with complex, difficult-to-treat atherosclerotic lesions and fast-progressing plaques. Click here to start: Join the Cardiometabolic Health Congress in Boston in 2024.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content